Oak Associates’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-6,190
| Closed | -$1.43M | – | 130 |
|
|
2024
Q2 | $1.43M | Hold |
6,190
| – | – | 0.1% | 90 |
|
|
2024
Q1 | $1.33M | Hold |
6,190
| – | – | 0.09% | 96 |
|
|
2023
Q4 | $1.6M | Sell |
6,190
-250
| -4% | -$61.4K | 0.12% | 89 |
|
|
2023
Q3 | $1.66M | Buy |
6,440
+250
| +4% | +$66.9K | 0.14% | 81 |
|
|
2023
Q2 | $1.76M | Hold |
6,190
| – | – | 0.14% | 82 |
|
|
2023
Q1 | $1.72M | Hold |
6,190
| – | – | 0.14% | 86 |
|
|
2022
Q4 | $1.71M | Hold |
6,190
| – | – | 0.14% | 89 |
|
|
2022
Q3 | $1.65M | Buy |
6,190
+835
| +16% | +$177K | 0.14% | 80 |
|
|
2022
Q2 | $1.09M | Hold |
5,355
| – | – | 0.09% | 97 |
|
|
2022
Q1 | $1.13M | Sell |
5,355
-650
| -11% | -$141K | 0.07% | 99 |
|
|
2021
Q4 | $1.44M | Sell |
6,005
-300
| -5% | -$77.1K | 0.08% | 97 |
|
|
2021
Q3 | $1.78M | Hold |
6,305
| – | – | 0.1% | 86 |
|
|
2021
Q2 | $2.18M | Sell |
6,305
-2,887
| -31% | -$875K | 0.12% | 74 |
|
|
2021
Q1 | $2.57M | Sell |
9,192
-8,081
| -47% | -$2.18M | 0.15% | 71 |
|
|
2020
Q4 | $4.23M | Hold |
17,273
| – | – | 0.26% | 55 |
|
|
2020
Q3 | $4.9M | Sell |
17,273
-3,050
| -15% | -$851K | 0.33% | 54 |
|
|
2020
Q2 | $5.44M | Buy |
20,323
+15
| +0.1% | +$4.51K | 0.37% | 54 |
|
|
2020
Q1 | $6.42M | Sell |
20,308
-1,690
| -8% | -$513K | 0.53% | 50 |
|
|
2019
Q4 | $6.53M | Sell |
21,998
-2,150
| -9% | -$597K | 0.38% | 61 |
|
|
2019
Q3 | $5.62M | Buy |
24,148
+245
| +1% | +$57K | 0.35% | 65 |
|
|
2019
Q2 | $5.59M | Hold |
23,903
| – | – | 0.35% | 64 |
|
|
2019
Q1 | $5.65M | Sell |
23,903
-15
| -0.1% | -$4.72K | 0.35% | 64 |
|
|
2018
Q4 | $7.2M | Buy |
23,918
+8,433
| +54% | +$2.69M | 0.51% | 57 |
|
|
2018
Q3 | $5.47M | Buy |
15,485
+350
| +2% | +$121K | 0.33% | 64 |
|
|
2018
Q2 | $4.39M | Buy |
15,135
+365
| +2% | +$103K | 0.29% | 69 |
|
|
2018
Q1 | $4.04M | Hold |
14,770
| – | – | 0.28% | 71 |
|
|
2017
Q4 | $4.71M | Sell |
14,770
-270
| -2% | -$86.6K | 0.33% | 66 |
|
|
2017
Q3 | $4.71M | Hold |
15,040
| – | – | 0.35% | 64 |
|
|
2017
Q2 | $4.08M | Buy |
15,040
+1,970
| +15% | +$521K | 0.31% | 77 |
|
|
2017
Q1 | $3.57M | Buy |
13,070
+4,690
| +56% | +$1.33M | 0.29% | 79 |
|
|
2016
Q4 | $2.38M | Buy |
8,380
+430
| +5% | +$127K | 0.23% | 91 |
|
|
2016
Q3 | $2.23M | Buy |
7,950
+1,200
| +18% | +$355K | 0.23% | 94 |
|
|
2016
Q2 | $1.63M | Buy |
6,750
+4,950
| +275% | +$1.3M | 0.2% | 100 |
|
|
2016
Q1 | $469K | Buy |
+1,800
| New | +$475K | 0.06% | 125 |
|
Other funds holding BIIB
Oak Associates's BIIB Position: Q3 2024 in Review
Oak Associates sold out of Biogen (BIIB) in Q3 2024, closing a stake of 6,190 shares — an estimated $1.43M sold.
Oak Associates first reported a position in BIIB in Q1 2016 and held it in 34 quarters. The position peaked at $7.2M in Q4 2018. 916 funds tracked by Wall St. Rank hold BIIB as of Q3 2024.
- Oak Associates reported no remaining Biogen position as of Q3 2024 after selling out during the quarter.
- Oak Associates sold 6,190 Biogen shares in Q3 2024, an estimated $1.43M.
- Oak Associates first reported a position in Biogen in Q1 2016 and held it in 34 quarters.
- Oak Associates's Biogen position peaked at $7.2M in Q4 2018.
- 916 funds tracked by Wall St. Rank held Biogen as of Q3 2024.
Based on Oak Associates's 13F filing for Q3 2024, filed 12 Nov 2024.